Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity

Next Previous
X
Search
Trial Profile

A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Debio 0123 (Primary)
  • Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Debiopharm

    • Most Recent Events

    • 04 Jun 2024 Results(As of October 24, 2023, n=27 pts) evaluating Safety, pharmacokinetic, and preliminary antitumor activity of Debio 0123 as monotherapy, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 07 Mar 2024 According to a Debiopharm media release, this studys population is mainly female, burdened by fatal malignancies like Uterine Serous Carcinoma, Epithelial Ovarian Cancer and fallopian tube cancer which are well-known hard-to-treat cancers. Dr. Manish R. Sharma, Principal Investigator at the START Midwest, Michigan.
    • 07 Mar 2024 According to a Debiopharm media release, the first patient dosed in the expansion cohort in this study. Two out of the three expansion arms of the study will be using biomarkers to pre-select patients with different solid tumors while the third arm will be treating patients with recurrent serous endometrial carcinoma.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top